A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC

Inclusion Criteria: * Men or women 18 years or older with histologically or cytologically confirmed advanced non-squamous NSCLC (unresectable stage IIIB with pericardial or pleural effusion or stage IV/recurrent) * Measureable disease per RECIST criteria modified * ECOG performance status of 0 or 1 * Ability to take oral medications * Competent to give written informed consent Exclusion Criteria: * Current or prior history of CNS metastases * Any prior chemotherapy for advanced NSCLC * History of pulmonary hemorrhage or gross hemoptysis within 6 months prior to randomization * Prior targeted therapies * Known history of allergy or hypersensitivity to paclitaxel or carboplatin * History of arterial or venous thrombosis within 52 weeks prior to randomization * History of bleeding diathesis or non-pulmonary bleeding within 14 days prior to randomization * Peripheral neuropathy \> grade 1 per CTCAE Version 3.0 * Myocardial infarction, cerebrovascular accident, grade 2 or greater peripheral vascular disease, transient ischemic attack, congestive heart failure, percutaneous transluminal coronary angioplasty/stent, ongoing arrythmias requiring medication or unstable angina within 52 weeks prior to randomization * Any kind of disorder that compromises the ability of the subject to comply with the study procedures * Uncontrolled hypertension as defined by resting blood pressure \> 150/90 mm Hg. Anti-hypertensive medications are allowed if hypertension is stably controlled at the time of randomization. * Participation in therapeutic clinical trials or currently receiving other investigational treatment(s) within 30 days prior to randomization * Pregnant or breast feeding women * Known to be HIV, hepatitis B surface antigen, or hepatitis C positive